# Wolff-Parkinson-White Syndrome

Manage Wolff-Parkinson-White syndrome by recognizing pre-excited atrial fibrillation as an electrical emergency, avoiding AV-nodal blockers, and referring symptomatic or high-risk patients for electrophysiologic assessment and accessory-pathway ablation.

**Clinical question:** How should physicians identify, acutely manage, and risk-stratify patients with Wolff-Parkinson-White syndrome?

Updated: 2026-08-21T01:54:32.278587+00:00

## What matters in practice
- An irregular wide-complex tachycardia in a patient with pre-excitation should be treated as pre-excited atrial fibrillation until proven otherwise; a shortest pre-excited RR interval below 250 ms identifies increased risk for ventricular fibrillation. [1][8]
- Avoid AV-nodal blocking agents in pre-excited atrial fibrillation because preferential accessory-pathway conduction can precipitate ventricular fibrillation. [1][15]
- For hemodynamically stable pre-excited atrial fibrillation, intravenous procainamide or ibutilide are supported pharmacologic options; unstable patients require immediate electrical cardioversion. [1]
- Symptomatic ventricular pre-excitation warrants electrophysiologic study and consideration of catheter ablation; sudden cardiac death risk in WPW syndrome may approach 4% over a lifetime. [4]
- Asymptomatic pre-excitation requires individualized risk assessment incorporating arrhythmic symptoms, atrial fibrillation, age at recognition, congenital heart disease, occupation, competitive sport, and invasive pathway properties. [13][14]

## Recognize pre-excited atrial fibrillation before giving AV-nodal blockade

The decisive distinction is between a regular re-entrant tachycardia and atrial fibrillation conducting over an accessory pathway.

Treat an irregular wide-QRS tachycardia with beat-to-beat variation in QRS morphology and very rapid ventricular activation as pre-excited atrial fibrillation until an alternative diagnosis is established. In this setting, rapid antegrade conduction through the accessory pathway can produce ventricular rates capable of degenerating into ventricular fibrillation. [1][2]

Measure the shortest pre-excited RR interval on the presenting ECG when discernible. A shortest interval below 250 ms during atrial fibrillation predicts increased risk of ventricular fibrillation; a reported interval of 160 ms represents particularly rapid accessory-pathway conduction. [1][8]

Do not use AV-nodal blocking agents for pre-excited atrial fibrillation. AV-nodal blockade may shift conduction preferentially to the accessory pathway and increase the risk of ventricular tachycardia or ventricular fibrillation. [1][15]
- Baseline sinus-rhythm ECG: a short PR interval, delta wave, and widened QRS complex support manifest ventricular pre-excitation. [9][12][17]
- WPW syndrome denotes ventricular pre-excitation plus documented supraventricular tachycardia or symptoms consistent with supraventricular tachycardia; isolated ECG pre-excitation is WPW pattern. [20][4]
- A patient whose presenting tachyarrhythmia is pre-excited atrial fibrillation should be referred for electrophysiologic evaluation after stabilization because this phenotype identifies a potentially dangerous accessory pathway. [1][4]

*ECG-driven actions for tachyarrhythmia in a patient with ventricular pre-excitation. [1][9][12][15]*

| Clinical ECG pattern | Interpretation | Immediate action |
| --- | --- | --- |
| Irregular wide-complex tachycardia with rapid pre-excited beats | Pre-excited atrial fibrillation; shortest pre-excited RR interval <250 ms indicates increased ventricular-fibrillation risk. [1][8] | Assess hemodynamic stability; avoid AV-nodal blockers. [1][15] |
| Sinus rhythm with short PR, delta wave, and widened QRS | Manifest accessory-pathway conduction (WPW pattern). [9][12][17] | Determine whether prior palpitations, syncope, documented SVT, or atrial fibrillation establishes WPW syndrome and prompts EP evaluation. [4][13][20] |
| Wide QRS initially interpreted as right bundle-branch block | Inspect for a subtle delta wave and short PR interval that may reveal pre-excitation. [9] | Compare with prior ECGs and avoid assuming isolated bundle-branch block when clinical tachyarrhythmia is present. [9] |

## Stabilize pre-excited atrial fibrillation and choose a pathway-directed antiarrhythmic

Hemodynamic status determines whether cardioversion or drug therapy is the initial intervention.

For hemodynamic instability during pre-excited atrial fibrillation, perform immediate electrical cardioversion rather than attempting AV-nodal blockade. The clinical priority is termination of the unstable rhythm before degeneration to ventricular fibrillation. [1]

For hemodynamically stable pre-excited atrial fibrillation, intravenous procainamide or intravenous ibutilide are pharmacologic options. Ibutilide prolongs refractoriness in both the AV node and accessory pathway, whereas procainamide has relevant atrial myocardial effects and is used for acute termination in stable WPW-associated tachyarrhythmia. [1][15]

During acute procainamide treatment, use continuous cardiac monitoring, monitor blood pressure frequently, and stop infusion if QRS duration increases by 50% from baseline. Use caution in heart failure, hypokalemia, hypomagnesemia, hepatic impairment, renal impairment, myasthenia gravis, pregnancy, and breastfeeding when prolonged therapy is contemplated. [15]
- If the rhythm is pre-excited atrial fibrillation, the contraindicated strategy is AV-nodal blockade; the relevant alternative is electrical cardioversion when unstable or procainamide/ibutilide when stable. [1][15]
- After acute conversion, obtain a sinus-rhythm 12-lead ECG to document manifest pre-excitation and support accessory-pathway localization planning. A left lateral pathway, for example, may be suggested by the post-conversion pre-excitation pattern. [1]
- Correct hypokalemia and hypomagnesemia before or during antiarrhythmic treatment because these abnormalities are identified precautions for procainamide use. [15]

*Acute treatment selection for pre-excited atrial fibrillation. [1][15]*

| Patient state | First action | Drug and monitoring considerations |
| --- | --- | --- |
| Hemodynamically unstable | Immediate electrical cardioversion. [1] | Do not delay definitive rhythm termination for AV-nodal blockade. [1] |
| Hemodynamically stable | Use intravenous procainamide or intravenous ibutilide. [1] | With procainamide, continuously monitor QRS duration and blood pressure; discontinue if QRS widens by 50% from baseline. [15] |
| Any pre-excited atrial fibrillation | Avoid AV-nodal blocking agents. [1][15] | AV-nodal blockade can favor accessory-pathway conduction and precipitate ventricular tachycardia or ventricular fibrillation. [1][15] |

## Refer symptomatic patients for electrophysiologic study and accessory-pathway ablation

Symptoms or documented tachyarrhythmia move management from observation to pathway-focused risk assessment and definitive therapy.

Refer patients with ventricular pre-excitation plus palpitations, syncope, documented supraventricular tachycardia, or atrial fibrillation to cardiac electrophysiology. Symptomatic pre-excitation establishes WPW syndrome, for which electrophysiologic study and catheter ablation of the accessory pathway are recommended approaches in guideline-based risk management. [4][20]

Prior pre-excited atrial fibrillation is a high-risk clinical feature because the accessory pathway has demonstrated antegrade conduction during atrial fibrillation. In this phenotype, the shortest pre-excited RR interval is the key ECG risk marker; a value below 250 ms predicts increased risk of ventricular fibrillation. [1][8]

Catheter ablation is the definitive pathway-directed intervention after clinically significant pre-excitation or high-risk pathway assessment. In a longitudinal series of patients with antegrade accessory pathways, atrial fibrillation disappeared after loss of ventricular pre-excitation in 4 of 5 affected patients, supporting the accessory pathway as a modifiable arrhythmic substrate in selected patients. [3]
- Document the arrhythmia phenotype before EP referral: regular SVT, atrial fibrillation with pre-excitation, syncope temporally associated with palpitations, or incidental pre-excitation. [4][13][20]
- Review for congenital structural associations, particularly Ebstein malformation of the tricuspid valve and congenitally corrected transposition of the great arteries. [13][14]
- A normal structural and functional heart is common in pediatric WPW, but congenital heart disease changes procedural planning and risk assessment. [14]

### What the electrophysiology evaluation adds

EP assessment estimates the capacity for antegrade accessory-pathway conduction and identifies pathways considered high risk for future arrhythmic events. The shortest pre-excited RR interval during atrial fibrillation is regarded as a central electrophysiologic risk measure, although procedural conditions can affect invasive risk stratification in children. [22][4]

Do not equate absent symptoms with absent risk. In asymptomatic ventricular pre-excitation, the first arrhythmic event can be sudden cardiac death; therefore, the decision is whether clinical context and pathway testing justify prophylactic ablation rather than whether symptoms alone are present. [4][14]
- For a patient with prior atrial fibrillation, syncope, or high-consequence occupational or athletic exposure, discuss EP testing and ablation rather than relying on serial symptom surveillance alone. [13][14]
- Interpret EP-derived risk estimates in children with attention to anesthesia-related limitations and imperfect prediction of clinical risk. [22][14]

*Clinical features that should lower the threshold for electrophysiologic evaluation or ablation discussion. [4][13][14]*

| Feature | Risk implication | Next decision |
| --- | --- | --- |
| Documented pre-excited atrial fibrillation | Demonstrates antegrade accessory-pathway conduction during a rhythm that may deteriorate to ventricular fibrillation. [1][2] | EP referral and accessory-pathway ablation planning after acute stabilization. [1][4] |
| Syncope or other arrhythmic symptoms with pre-excitation | Clinical high-risk feature; symptomatic pre-excitation defines WPW syndrome. [13][20] | Perform EP-based risk assessment and discuss ablation. [4] |
| Male sex or WPW pattern recognized in the first two decades of life | Clinical high-risk features in asymptomatic pre-excitation assessment. [13] | Use in individualized EP referral and prophylactic-ablation discussion. [13] |
| Congenital heart disease, especially Ebstein anomaly or congenitally corrected transposition | Associated structural context for WPW and higher-complexity evaluation. [13][14] | Refer to electrophysiology with congenital heart disease expertise. [13][14] |
| Pilot, bus driver, competitive athlete, or other high-consequence activity | Consequences of a first arrhythmic event affect acceptable residual risk. [13][24] | Pursue formal risk assessment and shared decision-making about ablation and activity. [13][14] |

## Manage asymptomatic ventricular pre-excitation with individualized risk stratification

An incidental delta wave requires a risk conversation, not automatic reassurance or automatic ablation.

Distinguish asymptomatic ventricular pre-excitation from WPW syndrome by taking a targeted history for palpitations, exertional presyncope or syncope, documented atrial fibrillation, and prior emergency evaluations for tachycardia. Pre-excitation occurs in approximately 0.1% to 0.3% of the general population, while symptomatic pre-excitation carries a lifetime sudden cardiac death risk that may approach 4%. [4]

For truly asymptomatic patients, assess clinical risk modifiers: male sex, discovery in the first two decades of life, history of atrial fibrillation, arrhythmic symptoms—particularly syncope—congenital heart disease, familial WPW syndrome, high-risk occupation, and moderate- to high-intensity competitive sport. These features should lower the threshold for EP referral and discussion of prophylactic ablation. [13]

Noninvasive or invasive testing is used to evaluate the rate of antegrade AV conduction over the accessory pathway. EP study may identify patients at high risk for future arrhythmic events, and accessory-pathway ablation should be considered when high-risk properties are found. [4][13]
- Do not use intermittent versus persistent pre-excitation as the sole reassuring branch in pediatric decision-making; contemporary pediatric algorithms consider both together because newer data have challenged prior assumptions about intermittent pre-excitation. [14]
- For children and families, use shared decision-making regarding ablation and activity restrictions because symptoms and EP findings are imperfect predictors of malignant arrhythmia. [14]
- For commercial driving or aviation certification, absence of symptoms and assessment by a cardiac specialist are required considerations. [13]

### When observation remains reasonable

Observation may be selected for an asymptomatic patient after individualized assessment when the anticipated procedural tradeoff does not favor immediate prophylactic ablation. This is a shared decision because asymptomatic pre-excitation is not risk-free, EP testing is an imperfect predictor, and the implications of a first event vary substantially by age, activity, and occupation. [4][13][14]
- Reclassify the patient as symptomatic and expedite EP review if palpitations, syncope, documented SVT, or atrial fibrillation develops. [4][13][20]
- Give clear emergency instructions for a sustained rapid palpitations episode, especially if associated with syncope, hypotension, chest discomfort, or dyspnea, because pre-excited atrial fibrillation may be life-threatening. [1][2]

*Risk-stratification framework for incidental ventricular pre-excitation. [4][13][14][22]*

| Assessment domain | Finding that increases concern | Management consequence |
| --- | --- | --- |
| Clinical history | Syncope, atrial fibrillation, or symptomatic tachyarrhythmia. [13][20] | Treat as symptomatic pre-excitation; refer for EP assessment and ablation discussion. [4] |
| Patient context | Young age at detection, male sex, familial WPW, congenital heart disease, high-risk occupation, or competitive sport. [13] | Lower threshold for formal pathway risk assessment. [13][14] |
| Invasive pathway evaluation | High-risk antegrade conduction properties; shortest pre-excited RR interval during atrial fibrillation is a key measure. [4][22] | Consider prophylactic accessory-pathway ablation. [4][13] |
| Pediatric interpretation | Intermittent or persistent pre-excitation. [14] | Do not use intermittency alone to exclude risk; incorporate shared decision-making and EP findings. [14] |

## Use rhythm documentation and risk reclassification to guide follow-up

Longitudinal management changes when symptoms, atrial fibrillation, or high-risk life circumstances emerge.

At each follow-up, ask specifically about documented or suspected atrial fibrillation, rapid irregular palpitations, exertional syncope, and emergency presentations for tachycardia. A transition from asymptomatic ECG pre-excitation to symptoms consistent with SVT changes the diagnosis to WPW syndrome and strengthens the indication for EP evaluation. [4][20]

Review the baseline and post-event ECGs for persistent delta waves, PR interval shortening, and QRS morphology; subtle pre-excitation can be mistaken for bundle-branch block. Preserve ECGs that capture pre-excited atrial fibrillation because the shortest pre-excited RR interval directly informs ventricular-fibrillation risk assessment. [1][9]

After accessory-pathway ablation, clinical follow-up should focus on recurrent palpitations or atrial arrhythmia symptoms and on whether ventricular pre-excitation is absent on ECG. Loss of ventricular pre-excitation was associated with disappearance of atrial fibrillation in most affected patients in one longitudinal series, but recurrence symptoms still warrant rhythm documentation and EP reassessment. [3]
- For any recurrent irregular wide-complex tachycardia, repeat the acute pathway: assess stability, avoid AV-nodal blockade, and use cardioversion when unstable or procainamide/ibutilide when stable. [1][15]
- For patients receiving acute procainamide, document QRS and blood-pressure monitoring and stop treatment for 50% QRS widening from baseline. [15]
- Revisit occupational, aviation, driving, and athletic implications whenever the patient’s work or competitive activity changes. [13][24]

*Follow-up triggers that should change management. [1][3][4][9][13][15][20]*

| Follow-up finding | Interpretation | Action |
| --- | --- | --- |
| New palpitations, syncope, documented SVT, or atrial fibrillation | Previously asymptomatic pre-excitation may now meet criteria for WPW syndrome. [20][4] | Obtain rhythm documentation and refer to EP for pathway assessment and ablation discussion. [4] |
| Irregular wide-complex tachycardia with rapid pre-excitation | Possible pre-excited atrial fibrillation with ventricular-fibrillation risk. [1] | Use acute instability-based management; avoid AV-nodal blockers. [1][15] |
| Post-ablation recurrence of palpitations | Symptoms require reassessment despite prior pathway-directed therapy. [3] | Obtain ECG or rhythm capture and arrange EP reassessment if recurrent arrhythmia is documented. [3] |
| Subtle delta wave on surveillance ECG | Persistent pre-excitation can mimic bundle-branch block. [9] | Reassess ECG interpretation and clinical risk status rather than labeling isolated conduction disease. [9] |

## References
1. Atrial Fibrillation in Wolff-Parkinson-White Syndrome | JACC: Case Reports — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jaccas.2019.07.032
2. Lidocaine in Wolff-Parkinson-White Syndrome with Atrial Fibrillation — www.acpjournals.org — https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-84-1-44
3. Longitudinal Clinical and Electrophysiological Assessment of Patients With Symptomatic Wolff-Parkinson-White Syndrome and Atrioventricular Node Reentrant Tachycardia — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.cir.93.11.2023
4. Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109715062026
5. Clinical features of Wolff-Parkinson-White syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002870399701407
6. Long term risk of Wolff-Parkinson-White pattern and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S105017381630192X
7. Practice Guideline Risk stratification for arrhythmic events ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S154752711501187X
8. Wolff‐Parkinson‐White Syndrome and Adenosine ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/pace.12089
9. Wolff‐Parkinson‐White Syndrome Mimics a Conduction ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2014/789537
10. white syndrome using ECG- based multi- task deep learning — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/eci.14385
11. Transesophageal Atrial Pacing for the Evaluation of ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111%2Fanec.70084
12. An Unusual Case of Supraventricular Tachycardia in a 64 ... — agsjournals.onlinelibrary.wiley.com — https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.13287
13. Asymptomatic Ventricular Preexcitation (Wolff-Parkinson ... — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2022/02/17/13/25/asymptomatic-ventricular-preexcitation
14. Clinical Practice Algorithms For Wolff-Parkinson-White Pattern in Pediatric Patients - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2025/08/13/10/27/clinical-practice-algorithms-for-wolff-parkinson-white-pattern-in-pediatric-patients
15. Procainamide - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK557788
16. Sudden Cardiac Death: A Pediatrician's Role — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/40/9/456/35325/Sudden-Cardiac-Death-A-Pediatrician-s-Role
17. Cardiac Arrhythmias | Pediatric Care Online — publications.aap.org — https://publications.aap.org/pediatriccare/article/doi/10.1542/aap.ppcqr.396053/1565/Cardiac-Arrhythmias
18. SIDS, BRUE, and Safe Sleep Guidelines Sudden ... — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/828549
19. A 3079 — publications.aap.org — https://publications.aap.org/books/chapter-pdf/1338130/aap_9781610020473-index.pdf
20. 2015 ACC/AHA/HRS Guideline for the Management of ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109715058404
21. Management of asymptomatic ventricular preexcitation — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0972629219301275
22. Difficulties with invasive risk stratification performed under anesthesia in pediatric Wolff-Parkinson-White Syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S154752711930832X
23. Risk assessment of pre-excitation: Atrial fibrillation versus ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S221402712200197X
24. Practice Variation in the Evaluation and Management of ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2772963X2500393X

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.